Security Snapshot

Tempest Therapeutics, Inc. - Common Stock, par value $0.001 per share (TPST) Institutional Ownership

CUSIP: 87978U207

13F Institutional Holders and Ownership History from Q1 2025 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

19

Shares (Excl. Options)

1.02MFull value: 1,024,557 · shares · 30 Jun 2026

Price

$1.11

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, par value $0.001 per share
Symbol
TPST on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
1,024,557
Latest holder snapshot 5 signals
Total 13F value
$1,137,238
Portfolio coverage rank
0%
Share change
+507,426
Value change
+$539,470
Number of holders
19
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
13,473,733
SEC-reported price per share
$0.74
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • TPST - Tempest Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 87978U207.
  • 19 institutions reported positions in Q2 2026.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 20 to 19 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $848.11KFull value: $848,109 · USD · 31 Mar 2026
    to
    $1.14MFull value: $1,137,238 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 19 institutions filings for Q2 2026.

Open SEC evidence

Security key

87978U207

13F reference period

Q2 2026

13F holders

19

13D/G owners

2

CIK / CUSIP context first

Open Q2 2026 holders TPST full holder history Tempest Therapeutics, Inc. SEC filings Tempest Therapeutics, Inc. company facts Tempest Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
2
Security
TPST
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Angel Matthew 36% $13,205,201 4,837,070 Matthew Angel 03 Feb 2026
SABBY MANAGEMENT, LLC 9.9% $1,397,913 492,223 SABBY MANAGEMENT, LLC 31 Dec 2025
As of 30 Jun 2026, 19 institutional investors reported holding
1.02MFull value: 1,024,557 · shares · 30 Jun 2026
shares of Tempest Therapeutics, Inc. - Common Stock, par value $0.001 per share (TPST). This represents 7.6% of the company’s total
13.47MFull value: 13,473,733 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
7
Headline period
Q2 2026
Rows shown
1-7 of 7
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 87,800 $73,502 +$1,183 $0.84 3
2026 Q2 1,024,557 $1,137,238 +$539,470 $1.11 19
2026 Q1 517,131 $848,109 -$242,423 $1.64 20
2025 Q4 517,764 $1,485,974 +$539,434 $2.87 19
2025 Q3 316,052 $3,248,899 -$2,235,429 $10.28 16
2025 Q2 674,784 $4,588,483 +$1,995,038 $6.80 17
2025 Q1 3,507,822 $2,588,773 +$2,588,773 $0.74 2
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .